Scarica l'app Stockscreener
8.22
2.95%
-0.25
Dopo l'orario di chiusura:
8.65
0.43
+5.23%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$8.47
Aprire:
$8.26
Volume 24 ore:
766.66K
Relative Volume:
1.44
Capitalizzazione di mercato:
$516.91M
Reddito:
-
Utile/perdita netta:
$-117.81M
Rapporto P/E:
-4.3723
EPS:
-1.88
Flusso di cassa netto:
$74.30M
1 W Prestazione:
-8.87%
1M Prestazione:
-2.26%
6M Prestazione:
+107.05%
1 anno Prestazione:
+138.26%
Intervallo 1D:
$8.09
$8.53
Intervallo di 1 settimana:
$8.09
$9.285
Portata 52W:
$2.612
$13.60
Omeros Corporation Stock (OMER) Company Profile
Nome
Omeros Corporation
Settore
Industria
Telefono
206-676-5000
Indirizzo
201 ELLIOTT AVENUE WEST, SEATTLE, WA
Confronta OMER con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OMER
Omeros Corporation
|
8.22 | 516.91M | 0 | -117.81M | 74.30M | -1.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Omeros Corporation Stock (OMER) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-23 | Iniziato | D. Boral Capital | Buy |
| 2024-11-14 | Iniziato | Rodman & Renshaw | Buy |
| 2022-12-08 | Downgrade | UBS | Buy → Neutral |
| 2022-11-08 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-06-08 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-10-08 | Downgrade | JP Morgan | Neutral → Underweight |
| 2021-10-01 | Downgrade | Maxim Group | Buy → Hold |
| 2021-10-01 | Downgrade | Wedbush | Neutral → Underperform |
| 2021-09-27 | Iniziato | JP Morgan | Neutral |
| 2021-02-01 | Iniziato | UBS | Buy |
| 2020-10-20 | Iniziato | BofA Securities | Buy |
| 2020-08-21 | Reiterato | H.C. Wainwright | Buy |
| 2020-08-14 | Reiterato | Maxim Group | Buy |
| 2019-05-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-07-12 | Iniziato | Seaport Global Securities | Buy |
| 2018-03-23 | Downgrade | Wedbush | Outperform → Neutral |
| 2018-03-05 | Downgrade | Needham | Buy → Hold |
| 2017-11-08 | Iniziato | H.C. Wainwright | Buy |
| 2017-05-11 | Downgrade | Cantor Fitzgerald | Buy → Neutral |
| 2017-03-17 | Reiterato | Maxim Group | Buy |
| 2017-03-17 | Reiterato | Needham | Buy |
| 2016-11-16 | Reiterato | Wedbush | Outperform |
| 2016-11-10 | Reiterato | Needham | Buy |
| 2016-08-10 | Reiterato | Maxim Group | Buy |
| 2016-06-03 | Iniziato | Cantor Fitzgerald | Buy |
| 2016-03-02 | Reiterato | Needham | Buy |
| 2016-02-29 | Reiterato | Wedbush | Outperform |
| 2015-11-11 | Reiterato | Needham | Buy |
| 2015-08-18 | Reiterato | WBB Securities | Strong Buy |
| 2015-08-10 | Iniziato | ROTH Capital | Buy |
Mostra tutto
Omeros Corporation Borsa (OMER) Ultime notizie
Earnings call transcript: Omeros Q4 2024 sees narrower EPS loss, stock climbs - Investing.com India
Omeros: Q4 Earnings Snapshot - MySA
Omeros beats Q4 earnings estimates, shares rise 5% - Investing.com
OMEROS CORP SEC 10-K Report - TradingView
Omeros Corporation Reports Fourth Quarter and Year-End 2024 Financial Results - Yahoo Finance
Omeros (OMER) to Release Quarterly Earnings on Monday - Defense World
Top Wall Street Forecasters Revamp Omeros Price Expectations Ahead Of Q4 Earnings - Benzinga
In the Green: Omeros Corporation (OMER) Closes at 8.52, Up/Down -6.99 from Previous Day - DWinneX
Omeros Corporation (OMER) Stock: A 52-Week Tale of Drops and Gains - The InvestChronicle
Trend Tracker for (OMER) - news.stocktradersdaily.com
Strong Buy Rating for Omeros Corporation Driven by Promising Narsoplimab Prospects and Strategic Advancements - TipRanks
Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 31, 2025 - Joplin Globe
Charles Schwab Investment Management Inc. Decreases Stock Holdings in Omeros Co. (NASDAQ:OMER) - Defense World
Bank of New York Mellon Corp Sells 4,919 Shares of Omeros Co. (NASDAQ:OMER) - Defense World
Omeros to activate site for Phase III programme of zaltenibart for PNH - Yahoo Finance
Omeros Co. (NASDAQ:OMER) Shares Sold by Bank of New York Mellon Corp - The AM Reporter
D. Boral Capital Reaffirms Buy Rating for Omeros (NASDAQ:OMER) - Defense World
Omeros (OMER) Expected to Announce Earnings on Monday - Defense World
Omeros advances Phase 3 trials for PNH treatment zaltenibart - Investing.com
Omeros Says Trial Site Activation Underway for Phase 3 Study of Zaltenibart -March 21, 2025 at 12:53 pm EDT - MarketScreener
Omeros advances Phase 3 trials for PNH treatment zaltenibart By Investing.com - Investing.com South Africa
Omeros Corporation Provides Update of Ongoing Zaltenibart Phase 3 PNH Clinical Trial Program - The Joplin Globe
Omeros (NASDAQ:OMER) Downgraded by StockNews.com to Sell - Defense World
US Bancorp DE Takes $81,000 Position in Omeros Co. (NASDAQ:OMER) - Defense World
Incyte, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
(OMER) On The My Stocks Page - Stock Traders Daily
Omeros Corporation Receives Commitment Of Over $4 Million From Nida For Further Development Of The Company'S Oms527 Program To Treat Cocaine Use Disorder - Marketscreener.com
Omeros Corporation Receives Commitment of Over $4 Million from NIDA for Further Development of the Company’s OMS527 Program to Treat Cocaine Use Disorder - Yahoo Finance
Major Breakthrough: First-Ever Cocaine Addiction Drug Receives $4M NIDA Funding - Stock Titan
Omeros (NASDAQ:OMER) Stock Rating Upgraded by StockNews.com - Defense World
Omeros Co. (NASDAQ:OMER) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Omeros (NASDAQ:OMER) Rating Lowered to Sell at StockNews.com - Defense World
New York State Common Retirement Fund Increases Stake in Omeros Co. (NASDAQ:OMER) - Defense World
The time has not yet come to remove your chips from the table: Omeros Corporation (OMER) - SETE News
Investor Network: Omeros Corporation to Host Earnings Call - ACCESS Newswire
Blue Trust Inc. Sells 1,910 Shares of Omeros Co. (NASDAQ:OMER) - Defense World
Loss-Making Omeros Corporation (NASDAQ:OMER) Expected To Breakeven In The Medium-Term - Simply Wall St
Omeros Corporation: Scientifically Compelling Again, But The Delay Has Cost Us (OMER) - Seeking Alpha
Trading (OMER) With Integrated Risk Controls - Stock Traders Daily
Omeros Corporation Announces Statistical Analysis Results for Expanded Access ProgramSeattle, Washington–(BUSINESS WIRE)–Feb 20, 2025–Omeros Corporation (NASDAQ: OMER) announced today the statistical analysis results related to the expande - Defense World
Omeros announces results for narsoplimab expanded access program - Yahoo Finance
Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA - Business Wire
Can This Drug Cut Death Risk by 66% in Transplant Patients? New Data Reveals Breakthrough - Stock Titan
Brokerages Set Omeros Co. (NASDAQ:OMER) Price Target at $22.50 - MarketBeat
Omeros Corporation Announces Availability on its Website of Materials Accompanying Narsoplimab Presentations at the 2025 Tandem Meetings - Business Wire
Breakthrough TA-TMA Treatment Data: Narsoplimab Shows Promising Results in 128-Patient Study - StockTitan
Omeros Co. (NASDAQ:OMER) Given Average Rating of “Moderate Buy” by Analysts - Defense World
Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program - BioSpace
Omeros Corporation Announces Upcoming Presentations Detailing Outcomes Of Narsoplimab Treatment For Ta-Tma - Marketscreener.com
Institutions own 43% of Omeros Corporation (NASDAQ:OMER) shares but retail investors control 53% of the company - Yahoo Finance
SG Americas Securities LLC Has $241,000 Position in Omeros Co. (NASDAQ:OMER) - Defense World
Omeros Corporation Azioni (OMER) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.05%
1.79%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):